GlassScriptPhysician profile
John Joseph Griffin
NPI 1740254440
$2,088.58
in general payments reported to CMS, 2019-2025
26 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.50 · 2020: $320 · 2021: $491 · 2022: $261 · 2023: $601 · 2024: $237 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $358.88 | 2020-2025 | |
| Biotronik INC. | $263.77 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Zero Gravity |
| Janssen Pharmaceuticals, INC | $219.31 | 2020-2022 | |
| Baxter Healthcare | $212.02 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Amgen INC. | $150.49 | 2020-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $137.50 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $90.34 | 2024 | (Cm9) Amb Mon & Diag Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.24 | 2020-2022 | |
| Pfizer INC. | $65.66 | 2021-2025 | |
| Abbott Laboratories | $64.89 | 2023 | Merlin@Home, Diamondback Coronary |
| Astrazeneca Pharmaceuticals LP | $56.48 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $48.48 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $46.43 | 2020 | |
| Irhythm Technologies, INC. | $33.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $33.49 | 2023 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.08 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.15 | 2022-2024 | Camzyos |
| Cardiovascular Systems INC. | $25.56 | 2021 | |
| Cordis US Corp. | $23.54 | 2023 | Rain Sheath Transradial |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.58 | 2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $21.11 | 2025 | Evkeeza |
| Boston Scientific Corporation | $20.10 | 2024 | |
| Esperion Therapeutics, INC. | $17.39 | 2021 | |
| Chiesi USA, INC. | $14.62 | 2020 | |
| Medtronic, INC. | $14.36 | 2021 | |
| Novo Nordisk INC | $13.21 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.